Mitigating Myocardial Injury
Novel TLR4 inhibitors as potential cardioprotective therapeutic agents following myocardial infarction (MI)
A myocardial infarction, or heart attack, occurs when a part of the heart muscle doesn’t receive enough blood flow due to a blockage, usually a blood clot. This blockage deprives the affected area of oxygen and nutrients, leading to the death of heart muscle cells. The extent of damage depends on factors like the location and duration of the blockage. A heart attack can result in necrosis (cell death) of heart tissue, the formation of scar tissue, impaired heart function, and potential complications like arrhythmias and heart failure.
Inventors
Contact info
Sari Prutchi Sagiv PhD Director of Pharma and Diagnostics
For further information please contact:
sari@mor-research.comWe have developed a novel, non-toxic, cardio-protective peptidomimetic (small molecule) candidate that ameliorated myocardial infarction (MI) .
We investigated the ability of the synthetized peptidomimetics to reduce both hypoxic and septic-like cardio-damage in vitro and in vivo. In several cardiac damage models our novel peptidomimetics showed very promising biological results, including:
The survival rate, measured at 24 hours following MI in the treated group was 100% compared to 58% of the controls subjected to MI .
The Infarct size was significantly smaller following 7 days in the treated group.
Enzymes leakage at 7 days following MI (CK LDH and Troponin) was significantly lower in the LT 87 treated group when compared to the controls.
Myocardial infarction is a significant health issue worldwide, and the market related to its treatment and management is of a substantial size. The prevalence of the disease approaches three million people worldwide, with more than one million deaths in the United States annually.